Class 530/330 - 4 to 5 amino acid residues in defined sequence

Subclass of Class 530 - Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
Definition: Compounds comprising from 4 or 5 amino acid residues of
No. of patents: 1733
Last issue date: 09/29/2009

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

Number	Title	Issue Date
7595374	Heparin binding motif and use thereof A method for reducing cytotoxicity of eosinophil derived toxins comprising administering to a subject an effective amount of heparin, heparan sulfate, a potent heparanase inhibitor or a polypeptide which has sequence as follows: BZBXBX, XBBBXXBX, XBBXBX, BBXXBBBXXBB...	09/29/2009
7547760	Peptides and chemical compound for inhibition of SHP2 function The present invention relates to the inhibition of the function of SHP2 by both anti-SHP2 peptides and the chemical compound 4-(2-sulfaminoethyl)benzoic acid, SEBA, and SEBA derivatives binding to the phosphotyrosyl phosphatase domain of SHP2 thereby inhibiting the ...	06/16/2009
7501486	Peptides that selectively home to heart vasculature and related conjugates and methods The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treat...	03/10/2009
7498405	Halogen-substituted thienyl compounds Halogen substituted thienyl compounds exhibit potential as nucleic acid (especially double stranded DNA) binders and as antibiotic compounds. A representative thienyl compound has the structure ...	03/03/2009
7456253	Growth hormone releasing peptides Disclosed are peptide and peptidomimetic compounds generally according to formula (I), and pharmaceutically acceptable salts thereof, that are useful as GHRP analogs: R1-A2-A3-A4-A5-R2 (I) or a pharma...	11/25/2008
7439345	Supramolecular pairing system, its preparation and use The invention relates to conjugates including at least one linker, a biomolecule coupled to the linker, and cyclohexane derivatives of the following formula: and oligomers thereof. ...	10/21/2008
7435718	CXCR4 antagonist treatment of hematopoietic cells In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used...	10/14/2008
7425608	Method of making metallopeptides Method of making metallopeptides is provided, for use in biological, pharmaceutical and related applications. The metallopeptides are made of peptides, peptidomimetics and peptide-like constructs, and include a metal ion-binding region thereof which includes at leas...	09/16/2008
7425541	Enzyme-cleavable prodrug compounds The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are m...	09/16/2008
7423116	Pentapeptide compounds and uses related thereto Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can ...	09/09/2008
7423020	Treatment of mood disorders by administration of SMR1 This invention relates to the use of an agent that modulates the interaction between a SMR1 peptide and a metal-lopeptidase for the preparation of a medicament for preventing or treating a Central Nervous System disorder giving rise to a mental disorder. ...	09/09/2008
7417028	Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP ...	08/26/2008
7417030	Indazole peptidomimetics as thrombin receptor antagonists The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, athero...	08/26/2008
7417027	Linear and cyclic melanocortin receptor-specific peptides Linear and cyclic peptides are provided specific to one or melanocortin receptors, and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. In one embodiment, a linear peptide of the following general formula is provided:	08/26/2008
7413537	Directed evolution of disulfide-bonded micro-proteins The invention relates, in part, to a library of chimeric proteins, each chimeric protein including a mini-protein between about eight and about forty amino acids long, wherein the mini-protein has a single disulfide bond formed by a pair of invariant cysteines and h...	08/19/2008
7410950	Peptides of CaV2.2 that inhibit pain The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use o...	08/12/2008
7404948	Peptidic conjugates for alopecia prevention and treatment The invention relates to novel peptidic conjugates containing a Gly-His-Lys sequence and used for dermatology or cosmetology for stimulating hair growth or stopping hair fall. ...	07/29/2008
7402556	Prodrugs activated by plasmin and their use in cancer chemotherapy The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The ...	07/22/2008
7399825	Synthetic peptide, inhibitor to DNA viruses The present invention relates to the identification of the active domain of Herpoxin, a DNA virus-inhibiting-protein which was isolated from cobra venom in U.S. Pat. No. 5,648,339 and has a molecular weight of 13.5 kDa We have isolated a fragment of Herpoxin which c...	07/15/2008
7399630	Peptides for enhanced cell attachment and growth The present invention relates to cell adhesion promoting (“CAP”) peptide combinations that promote cell attachment or cell adhesion to culture surfaces that are otherwise cell adhesion resistant “CAR”. The invention provides combination of peptides that, whe...	07/15/2008
7396814	Metallopeptide compositions for treatment of sexual dysfunction Metallopeptide compositions are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. The metallopeptides include at least one, and preferably two, aromatic amino acid...	07/08/2008
7393835	Peptide inhibitors of protein kinase C PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating diseases states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulation...	07/01/2008
7390874	Peptide, method of production thereof, and pharmaceutical composition containing the same A biologically active peptide having the amino acid sequence tyrosine-glycine-serine-arginine-serine (SEQ ID NO: 1), as well as compositions prepared from such peptide, possessing anti-cancer activity and anti-inflammatory activity, and a method for producing such a...	06/24/2008
7387778	Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders The invention relates to the field of psychopharmacology. More particularly, the invention relates to the treatment of mental disorders, such as impaired interpersonal and behavioral disorders, including sexual disorders such as M.E.D. and H.S.D.D. The invention pro...	06/17/2008
7387879	Diagnosis of tauopathies The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present i...	06/17/2008
7385027	Membrane-permeable peptide capable of calpain inhibition 5-mer peptides that can inhibit calpain I and calpain II are disclosed. The peptide sequence is as follows: Leu or Ala)-(Xaa)-(Asp or Glu)-(Xaa)-(Leu or Met), where Xaa can be any amino acid. ...	06/10/2008
7385028	Derivatization of non-natural amino acids and polypeptides Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can includ...	06/10/2008
7385025	Metallopeptide compounds Metallopeptides with a sequence of a biologically active alpha-melanocyte stimulating hormone (α-MSH), gamma-melanocyte stimulating hormone (γ-MSH), or bombesin sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each availab...	06/10/2008
7385029	Method of making tetrapeptide derivative TZT-1027 crystal The invention provides crystals of N2-(N,N-dimethyl-L-valyl)-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-[(S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide or salts thereof which p...	06/10/2008
7381707	Treatment of dry eye The present invention relates to methods to treat dry eye in a mammal by intraocularly administering a composition comprising a peptide. ...	06/03/2008
7378396	Therapeutic agents and methods for cardiovascular disease The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (...	05/27/2008
7378397	TRH-degrading ectoenzyme inhibitors Peptide derivatives useful as inhibitors of activity of thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) are of formula Ia: wherein: R1 is an optionally su...	05/27/2008
7375083	Pharmaceutical compositions for prevention of overdose or abuse The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the phar...	05/20/2008
7375082	Abuse-resistant hydrocodone compounds The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resi...	05/20/2008
7368421	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis The present invention provides a new use of DP IV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DP IV or DP IV-like enzymes, such as imm...	05/06/2008
7368433	Peptides and methods for the control of obesity The subject invention provides novel peptides for use in treating mammals to control appetite and obesity. Disclosed is a peptide derivative having the formula: X1-Z-Q-arg-trp-NH2 wherein: X1 is an acyl group, Z i...	05/06/2008
7368119	Compositions and methods for WT1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that sp...	05/06/2008
7368528	Antineoplastic peptides The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO-A-B-D-E-(G)s-K I wherein R1, R2, X, A, B, D, E, G, K, and s have the meanings stated in the description. ...	05/06/2008
7365155	Immunoregulator The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides among others an immunoregulator (NMP...	04/29/2008
7365047	Use of pentagastrin to inhibit gastric acid secretion or as a diuretic This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion. ...	04/29/2008

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

PatentStorm

Quotables

PatentStorm News

Class 530/330 - 4 to 5 amino acid residues in defined sequence